S. 5297 · 119th Congress · Health

American Pharmaceutical Security Act

In committee247 words Introduced Aug 6, 2026 · Latest action Aug 6, 2026

How far it has goneStage 2 of 6
  1. IntroducedAug 6, 2026 Done
  2. CommitteeReferred to Finance Current stage
  3. Senate floorNot yet Not reached yet
  4. House floorNot yet Not reached yet
  5. Chambers agreeNot yet Not reached yet
  6. PresidentNot yet Not reached yet

Full text

No CRS summary yet · 247 words

S. 5297 · Introduced in Senate · Aug 6, 2026

SECTION 1. SHORT TITLE.

This Act may be cited as the American Pharmaceutical Security Act .

SEC. 2. REPORT ON MARKETS FOR API AND KEY STARTING MATERIALS.

(a) In general. Not later than 1 year after the date of enactment of this Act, the Administrator of the Centers for Medicare & Medicaid Services (referred to in this section as the Administrator ) shall submit to Congress a report on its findings and policy recommendations regarding the use of coverage and reimbursement authorities to protect the markets of the United States and its allies for active pharmaceutical ingredients and key starting materials and reduce direct and indirect dependence on foreign adversaries (as described in section 791.4 of title 15, Code of Federal Regulations (or any successor regulations)) for such ingredients and materials.

(b) Contents. The report under subsection (a)— (1) may include— (A) recommendations for price floor commitments in support of domestic manufacturing of active pharmaceutical ingredients and key starting materials to protect investments in the domestic markets of such ingredients and materials against nonmarket practices and price manipulation; and (B) recommendations that would prioritize domestically manufactured active pharmaceutical ingredients and key starting materials over foreign manufactured active pharmaceutical ingredients and key starting materials when a domestic source for the applicable ingredient or material exists; and (2) shall identify any existing gaps in data and information related to the origin and ownership of active pharmaceutical ingredients and key starting materials that the Administrator would need to implement the recommendations included in the report.

Shown here because the text is under 500 words. Open on Congress.gov

Who lobbies on it

No lobbying filing on file names S. 5297.

Organizations that named S. 5297 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.

Actions

2 actions · newest first
  1. Aug 6, 2026Read twice and referred to the Committee on Finance.
  2. Aug 6, 2026Introduced in Senate